Literature DB >> 10975220

Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.

V Rigalleau1, B Gatta, S Bonnaud, M Masson, M L Bourgeois, V Vergnot, H Gin.   

Abstract

AIMS: Atypical anti-psychotic drugs (APDs) are widely used in psychotic disorders refractory to conventional neuroleptic agents.
RESULTS: Three cases of new-onset diabetes are reported in Caucasian men who were on clozapine (one) or olanzapine (two) for 3-6 months. They had a distinct presentation: weight loss, ketosis (one ketoacidosis), severe hyperglycaemia requiring insulin therapy, and relative insulin deficiency as reflected by glucagon stimulatory tests. In all cases, insulin was stopped within 1 month after the APD was discontinued.
CONCLUSIONS: Novel APDs not only induce diabetes as a result of weight gain in predisposed patients, but can also lead to a reversible state of insulin deficiency, and sometimes ketoacidosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975220     DOI: 10.1046/j.1464-5491.2000.00296.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

1.  Weight gain and new onset diabetes associated with olanzapine and risperidone.

Authors:  Wildon R Farwell; Timothy E Stump; Jane Wang; Eskinder Tafesse; Gilbert L'Italien; William M Tierney
Journal:  J Gen Intern Med       Date:  2004-12       Impact factor: 5.128

Review 2.  Atypical antipsychotics and diabetic ketoacidosis: a review.

Authors:  Melanie D Guenette; Margaret Hahn; Tony A Cohn; Celine Teo; Gary J Remington
Journal:  Psychopharmacology (Berl)       Date:  2013-01-24       Impact factor: 4.530

Review 3.  Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Authors:  John W Newcomer
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Diabetes in a high secure hospital.

Authors:  I A MacFarlane; G V Gill; D Finnegan; J Pinkney
Journal:  Postgrad Med J       Date:  2004-01       Impact factor: 2.401

Review 6.  Hyperglycemia with antipsychotic treatment.

Authors:  Roopa Sathyaprakash; Robert R Henry
Journal:  Curr Diab Rep       Date:  2004-02       Impact factor: 4.810

Review 7.  Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications.

Authors:  Kristina Melkersson; Marja-Liisa Dahl
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study.

Authors:  Carol E Koro; Donald O Fedder; Gilbert J L'Italien; Sheila S Weiss; Laurence S Magder; Julie Kreyenbuhl; Dennis A Revicki; Robert W Buchanan
Journal:  BMJ       Date:  2002-08-03

Review 9.  Cardiometabolic effects of psychotropic medications.

Authors:  Oluchi Abosi; Sneha Lopes; Samantha Schmitz; Jess G Fiedorowicz
Journal:  Horm Mol Biol Clin Investig       Date:  2018-01-10

Review 10.  Treatment of Diabetic Ketoacidosis Associated With Antipsychotic Medication: Literature Review.

Authors:  Antonia Vuk; Maja Baretic; Martina Matovinovic Osvatic; Igor Filipcic; Nikolina Jovanovic; Martina Rojnic Kuzman
Journal:  J Clin Psychopharmacol       Date:  2017-10       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.